Radiotherapy for breast cancer, the TARGIT - A trial (V)

The Lancet

Volumn 383, Issue 9930, 2014, Pages 1718-1719

  Harness, Jay K ^a   Silverstein, Melvin J ^b,c   Wazer, David E ^d   Riker, Adam I ^e,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ADVOCATE CHRIST MEDICAL CENTER   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; EXTERNAL BEAM RADIOTHERAPY; HEART DEATH; HUMAN; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION INDUCED NEOPLASM; CLINICAL TRIAL (TOPIC); FOLLOW UP; RADIATION DOSE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS;

EID: 84900529126     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60829-1     Document Type: Letter

References (2)

1. Vaidya JS, Wenz F, Bulsara M., et al, on behalf of the TARGIT trialists' group. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 2014; 383: 603-13.
2. Darby SC, Ewertz M, McGale P., et al Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368: 987-98.